Core Viewpoint - The company, Huaqiang Technology, anticipates a net profit attributable to shareholders of the parent company for the fiscal year 2025 to be between 32.15 million and 48.20 million yuan, representing a year-on-year increase of 9.62 million to 25.67 million yuan, which translates to a growth rate of 42.70% to 113.94% [1] Group 1 - The company is actively pursuing military product orders, leading to an increase in military product revenue and improved product gross margins [1] - Adjustments in product and market structure have resulted in increased sales of new products, contributing to the enhancement of gross margins for civilian products [1] - Implementation of quality improvement and efficiency enhancement actions, along with cost-saving measures, has yielded effective results, leading to an overall improvement in production management levels [1]

Core Viewpoint - Huachang Technology's stock performance shows a slight increase, but financial metrics indicate a decline in revenue and profit, suggesting potential challenges ahead for the company [1][2]. Financial Performance - As of January 22, Huachang Technology's stock rose by 1.31%, with a trading volume of 43.09 million yuan [1]. - For the period from January to September 2025, the company reported a revenue of 266 million yuan, a year-on-year decrease of 22.36%, and a net profit attributable to shareholders of 4.44 million yuan, down 83.92% year-on-year [2]. Financing and Margin Data - On January 22, the financing buy amount was 3.90 million yuan, while the financing repayment was 5.70 million yuan, resulting in a net financing buy of -1.80 million yuan [1]. - The total margin balance as of January 22 was 91.63 million yuan, accounting for 1.23% of the circulating market value, which is below the 50th percentile level over the past year, indicating a low financing balance [1]. Shareholder Information - As of September 30, the number of Huachang Technology's shareholders was 18,700, a decrease of 17.81% from the previous period, while the average circulating shares per person increased by 21.67% to 18,428 shares [2]. - The company has distributed a total of 165 million yuan in dividends since its A-share listing, with 49.93 million yuan distributed over the past three years [3]. Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited was the ninth largest circulating shareholder, holding 1.1751 million shares as a new shareholder [3].

证券代码：688151 证券简称：华强科技 公告编号：2026-001 湖北华强科技股份有限公司 关于补选公司第二届董事会薪酬与考核委员会委员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 为完善湖北华强科技股份有限公司（以下简称"公司"）治理结构，健全董事会薪酬与考核委员会人员构 成，保证董事会薪酬与考核委员会有序开展各项工作，根据《中华人民共和国公司法》《上市公司治理 准则》及《公司章程》等有关规定，公司于2026年1月9日召开第二届董事会第十八次会议审议通过了 《关于补选公司第二届董事会薪酬与考核委员会委员的议案》，同意补选张亚昌先生（简历附后）为第 二届董事会薪酬与考核委员会委员，任期自公司本次董事会审议通过之日起至本届董事会届满之日止。 本次补选完成后，公司第二届董事会薪酬与考核委员会由王广昌（召集人）、张亚昌、刘颖斐组成。 特此公告。 湖北华强科技股份有限公司董事会 2026年1月10日 张亚昌先生简历 张亚昌，1967年出生，中国国籍，无境外永久居留权，机械设计与制造专业，本科学历，工程硕士学 位，正 ...

（文章来源：证券日报） 证券日报网讯 1月9日，华强科技发布公告称，同意补选张亚昌先生为第二届董事会薪酬与考核委员会 委员。 ...

湖北华强科技股份有限公司 关于补选公司第二届董事会薪酬与考核委 员会委员的公告 证券代码：688151 证券简称：华强科技 公告编号：2026-001 张亚昌，1967 年出生，中国国籍，无境外永久居留权，机械设计与制造专 业，本科学历，工程硕士学位，正高级工程师。1989 年 7 月至 2023 年 11 月， 历任贵州高峰石油机械股份有限公司设计研究所副所长、设计研究所所长、副总 工程师、技术中心主任、总经理助理、副总经理、董事、党委副书记、总经理、 党委书记、董事长；2023 年 12 月至今，担任中光学集团股份有限公司董事；2024 年 12 月至今，担任湖北华中长江光电科技有限公司董事；2023 年 12 月至今， 担任公司第二届董事会非独立董事。 2 附件： 张亚昌先生简历 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 为完善湖北华强科技股份有限公司（以下简称"公司"）治理结构，健全董 事会薪酬与考核委员会人员构成，保证董事会薪酬与考核委员会有序开展各项工 作，根据《中华人民共和国公司法》《上市公司治理准则》 ...

Core Viewpoint - The domestic aircraft carrier concept has seen a significant increase of 4.70%, leading the gains among concept sectors, with 33 stocks rising, including notable performers like Hailanxin, which hit a 20% limit up [1][2]. Group 1: Market Performance - The domestic aircraft carrier sector recorded a net inflow of 2.284 billion yuan, with 24 stocks experiencing net inflows, and 8 stocks exceeding 100 million yuan in net inflow [2]. - Hailanxin led the net inflow with 888.7 million yuan, followed by China Shipbuilding, AVIC Aircraft, and AVIC Xi'an Aircraft, with net inflows of 726 million yuan, 525 million yuan, and 281 million yuan respectively [2][3]. - The top gainers in the domestic aircraft carrier sector included Hailanxin (20%), China First Heavy Industries (10.07%), and AVIC Aircraft (9.99%) [1][3]. Group 2: Stock Performance - The stocks with the highest net inflow ratios included AVIC Heavy Industry (43.69%), China First Heavy Industries (38.62%), and Hailanxin (24.87%) [3]. - Other notable performers in terms of daily gains included AVIC Xi'an Aircraft (5.60%), China Shipbuilding (4.09%), and Taihao Technology (7.67%) [1][3]. - Conversely, stocks that experienced declines included Bowei Alloy (-1.04%), Zhenxin Technology (-0.31%), and Haohua Technology (-0.18%) [1][5].

Group 1 - The military equipment restructuring concept declined by 1.46%, ranking among the top declines in the concept sector, with Hunan Tianyan, Dong'an Power, and Construction Industry showing significant drops [1] - The military equipment restructuring concept experienced a net outflow of 353 million yuan in main funds today, with seven stocks seeing net outflows, and five stocks exceeding 10 million yuan in net outflows [2] - The stock with the highest net outflow was Changcheng Military Industry, which saw a net outflow of 163 million yuan, followed by Changan Automobile, Hunan Tianyan, and Dong'an Power with net outflows of 130 million yuan, 21.74 million yuan, and 18.23 million yuan respectively [2] Group 2 - The military equipment restructuring concept was among the worst performers today, with a notable decline compared to other sectors such as photolithography, which increased by 6.05% [2] - The outflow of funds from the military equipment restructuring concept indicates a lack of investor confidence, as evidenced by the significant net outflows from key stocks in the sector [2] - The trading volume for Changcheng Military Industry was 3.91%, indicating a relatively low turnover rate despite the significant net outflow [2]

Group 1 - Haitai Xinguang, based in Qingdao, specializes in the research, production, and sales of medical endoscope instruments and optical products, being a leading enterprise in the domestic medical endoscope optical field [1][30] - The company has established long-term collaborations with international medical giants such as Karl Storz and Olympus, and its high-definition optical imaging technology supports navigation equipment for neurosurgery [1][30] - By 2026, the market demand for its high-end optical components is expected to further release due to the recovery of the medical device sector and the advancement of brain-computer interface medical applications [1][30] Group 2 - Huqiang Technology, registered in Yichang, focuses on special protective equipment, pharmaceutical packaging, and medical devices, with a strong advantage in public health emergency material supply [2][31] - Its medical protective equipment is applicable in sterile operating environments for brain-computer interface implantation surgeries, enhancing product competitiveness in the medical device sector [2][31] Group 3 - Zhengde Medical, headquartered in Shaoxing, is a leading enterprise in the medical dressing industry, with a product matrix covering medical dressings, infection control, and rehabilitation care [3][32] - The company's surgical infection control products meet the sterile operation requirements for brain-computer interface implantation surgeries, and its rehabilitation products cater to post-operative patient management needs [3][32] - By 2026, the surgical infection control consumables business is expected to see market growth as brain-computer interface medical applications accelerate [3][32] Group 4 - Linuo Pharmaceutical Packaging, based in Jinan, specializes in the research, production, and sales of pharmaceutical packaging materials, including sterile medical device packaging suitable for brain-computer interface components [4][33] - The company is gradually expanding into the high-end medical device packaging market, seizing opportunities in the brain-computer interface industry [4][33] Group 5 - Rendu Biotech, located in Shanghai, focuses on RNA molecular diagnostic technology, with applications in infection detection post-brain-computer interface implantation surgeries [5][34] - The company’s post-operative infection detection reagents are expected to see new demand growth by 2026 as brain-computer interface clinical surgeries are promoted [5][34] Group 6 - Huangshan Capsule, based in Anhui, specializes in the research and production of pharmaceutical hollow capsules, gradually expanding into medical device auxiliary materials [6][36] - The company’s medical capsule carriers can adapt to the encapsulation needs of sustained-release bioelectrodes in brain-computer interface devices [6][36] Group 7 - ST Kelly, headquartered in Suzhou, focuses on medical device research and production, particularly in ultrasound equipment and rehabilitation devices [7][37] - The company’s ultrasound diagnostic equipment can be used for pre-operative brain tissue imaging assessments in brain-computer interface surgeries [7][37] Group 8 - Aotai Biotech, based in Hangzhou, specializes in rapid diagnostic reagents, with its rapid infection detection reagents applicable in brain-computer interface clinical settings [8][38] - The company is developing rapid detection products for post-operative neurological function assessment related to brain-computer interfaces [8][38] Group 9 - Dongfang Ocean, located in Yantai, focuses on marine biological medical materials, with collagen materials applicable as coatings for brain-computer interface electrodes [9][39] - The company is increasing its R&D investment in the medical device sector, particularly in the integration of biological medical materials with brain-computer interface devices by 2026 [9][39] Group 10 - Shuoshi Biotech, based in Taizhou, specializes in nucleic acid detection technology, with products applicable for precise diagnosis of post-operative brain infections in brain-computer interface surgeries [10][40] - The company is exploring detection technologies related to neurotransmitters in brain-computer interfaces, aiming for breakthroughs in neurological disease diagnostics [10][40] Group 11 - Guofa Co., located in Beihai, focuses on pharmaceutical manufacturing and medical device sales, with a distribution network covering Guangxi and surrounding areas [11][41] - The company plans to increase its agency layout for high-end medical devices related to brain-computer interfaces by 2026 [11][41] Group 12 - Nanwei Co., based in Nantong, specializes in medical dressings and hygiene products, with its adhesive dressings suitable for post-operative care in brain-computer interface surgeries [12][42] - The company is enhancing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [12][42] Group 13 - Mingde Biotech, located in Wuhan, is a leading enterprise in the field of rapid diagnostic reagents, with products applicable for monitoring vital signs during brain-computer interface surgeries [13][43] - The company is developing rapid assessment devices for post-operative neurological function related to brain-computer interfaces [13][43] Group 14 - Hualan Co., based in Wuxi, specializes in medical rubber products, with its rubber sealing components applicable in fluid control systems for brain-computer interface devices [14][44] - The company is collaborating with research institutions to develop rubber insulation components for brain-computer interface electrodes [14][44] Group 15 - Yuyue Medical, headquartered in Danyang, is a leading enterprise in home medical devices, with products applicable in brain-computer interface surgeries [15][45] - The company is increasing its R&D on medical-grade rehabilitation robots, aiming to integrate brain-computer interface technology with rehabilitation devices [15][45] Group 16 - Shengxiang Biotech, located in Changsha, focuses on nucleic acid detection technology, with products applicable for rapid diagnosis of central nervous system infections post-brain-computer interface surgeries [16][46] - The company is exploring gene detection technologies related to neurological genetic diseases, expanding the application boundaries of molecular diagnostics [16][46] Group 17 - Jiga Development, based in Jinan, focuses on high-end medical device incubation and industrialization, particularly in brain-computer interface-related medical device enterprises [17][47] - The company is responsible for industrial park construction and resource integration for brain-computer interface medical device companies [17][47] Group 18 - Anxu Biotech, located in Hangzhou, specializes in rapid diagnostic reagents, with products applicable for instant infection screening during brain-computer interface surgeries [18][48] - The company is developing rapid detection products for neurotransmitters related to brain-computer interfaces, aiming for breakthroughs in neurological function assessment [18][48] Group 19 - Wantai Biotech, based in Beijing, is a comprehensive enterprise in biopharmaceuticals and medical devices, with products applicable for biochemical index detection post-brain-computer interface surgeries [19][49] - The company is exploring biopharmaceutical development related to brain-computer interfaces, seeking new growth points in nerve repair [19][49] Group 20 - Jiuan Medical, located in Tianjin, focuses on home health devices, with products applicable for synchronized monitoring of brain signals and vital signs in brain-computer interface scenarios [20][50] - The company is increasing its R&D investment in brain-computer interface wearable devices, aiming to create an intelligent medical ecosystem [20][50] Group 21 - Jidan Biotech, based in Nanjing, specializes in POCT reagents and instruments, with products applicable for cardiovascular function assessment in brain-computer interface surgeries [21][51] - The company is developing rapid detection products for post-operative cerebrovascular diseases related to brain-computer interfaces [21][51] Group 22 - Wanfeng Biotech, located in Guangzhou, is a leading enterprise in the POCT field, with products applicable for instant infection screening during brain-computer interface surgeries [22][52] - The company is developing neurobiomarker detection reagents to assess post-operative neurological function recovery, providing comprehensive support for brain-computer interface surgeries [22][52] Group 23 - Haier Biotech, based in Qingdao, specializes in low-temperature storage devices for biological materials, with applications in brain-computer interface-related biological sample preservation [23][53] - The company is increasing its R&D on high-end medical storage devices tailored for brain-computer interface biological materials by 2026 [23][53] Group 24 - Haooubo, located in Suzhou, focuses on immune diagnostic reagents and instruments, with products applicable for immune function assessment in brain-computer interface surgeries [24][54] - The company is developing detection reagents for immune rejection post-brain-computer interface implantation, providing technical support for surgical complications [24][54] Group 25 - Shandong Pharmaceutical Glass, based in Zibo, is a leading enterprise in pharmaceutical glass, with products applicable for insulation packaging of brain-computer interface electrodes [25][55] - The company is expanding into the high-end medical device glass materials market, targeting the brain-computer interface industry [25][55] Group 26 - Innotech, located in Langfang, specializes in infectious disease diagnostic reagents, with products applicable for pre-operative lung infection screening in brain-computer interface surgeries [26][56] - The company is developing rapid detection products for post-operative lung infections related to brain-computer interfaces, aiming for breakthroughs in post-operative complication detection [26][56] Group 27 - Jianer Kang, based in Changzhou, focuses on medical dressings and rehabilitation care products, with its antibacterial medical dressings applicable for post-operative care in brain-computer interface surgeries [27][59] - The company is increasing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [27][59]

Core Points - The company announces the retirement of core technical personnel, Mr. He Huashan, who will no longer hold any position within the company after reaching the legal retirement age [1][2] - Mr. He Huashan indirectly holds 399,400 shares of the company, accounting for 0.12% of the total share capital [2] - During his tenure, Mr. He participated in the research and was involved in 26 authorized patents, including 3 invention patents, all of which belong to the company [3] - The company has confirmed that there are no disputes regarding the ownership of patents related to Mr. He's work, ensuring the integrity of the company's intellectual property [3] - The company has a robust research and development (R&D) system and does not rely heavily on any single core technical personnel, ensuring continuity in its operations [5] - The R&D team is stable and capable of supporting ongoing and future core technology development [5] - The company emphasizes the importance of R&D and plans to continue enhancing its R&D personnel recruitment and training efforts [7]

证券日报网讯 12月29日，华强科技发布公告称，核心技术人员贺华山先生因达到法定年龄退休，其退 休离任后不再担任公司核心技术人员，且不再担任公司任何职务。截至本公告日，贺华山先生间接持有 公司股份399，400股。 （文章来源：证券日报） ...